BRCA1 and neoplasm: Given their elevated mutational load and unique mutational signature, we hypothesized that BRCA1/2-mutated tumors may harbor more tumor-specific neoantigens, and therefore demonstrate, increased tumor-infiltrating lymphocytes (TILs) [7], as well as increased expression of immune checkpoint modulators PD-1 and PD-L1.